Safety assessment of excipients (SAFE) for orally inhaled drug products.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsMetz, Julia K
Lehr, Claus Michael
MetadataShow full item record
AbstractThe development of new orally inhaled drug products requires the demonstration of safety which must be proven in animal experiments. New in vitro methods may replace, or at least reduce, these animal experiments provided they are able to correctly predict the safety or eventual toxicity in humans. However, the challenge is to link human in vitro data to human in vivo data. We here present a new approach to the safety assessment of excipients (SAFE) for pulmonary drug delivery. The SAFE model is based on a dose response curve of 23 excipients tested on the human pulmonary epithelial cell lines A549 and Calu-3. The resulting in vitro IC50 values were correlated with the FDA-approved concentration in pharmaceutical products for either pulmonary (if available) or parenteral administration. Setting a threshold of 0.1% (1 mg/mL) for either value yielded four safety classes, allowed to link IC50 data as measured on human cell cultures in vitro with the concentrations of the same compounds in FDA-approved drug products. The necessary in vitro data for novel excipients can be easily generated while the SAFE approach allows putting them in the context for eventual use in human pulmonary drug products. Excipients, that are most likely not safe for use in humans, can be early excluded from further pharmaceutical development. The SAFE approach helps thus to avoid unnecessary animal experiments.
CitationALTEX. 2020 Jan 29. doi: 10.14573/altex.1910231.
AffiliationHIPS, Helmholtz-Institut für Pharmazeutische Forschung Saarland, Universitätscampus E8.1 66123 Saarbrücken, Germany.
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International
- A compilation of safety impact information for extractables associated with materials used in pharmaceutical packaging, delivery, administration, and manufacturing systems.
- Authors: Jenke D, Carlson T
- Issue date: 2014 Sep-Oct
- Safety of Excipients in Pediatric Formulations-A Call for Toxicity Studies in Juvenile Animals?
- Authors: Schmitt G
- Issue date: 2015 May 15
- An Overview of Pharmaceutical Excipients: Safe or Not Safe?
- Authors: Abrantes CG, Duarte D, Reis CP
- Issue date: 2016 Jul
- Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
- Authors: EFSA GMO Panel Working Group on Animal Feeding Trials.
- Issue date: 2008 Mar
- A Proposed In Vitro Method to Assess Effects of Inhaled Particles on Lung Surfactant Function.
- Authors: Sørli JB, Da Silva E, Bäckman P, Levin M, Thomsen BL, Koponen IK, Larsen ST
- Issue date: 2016 Mar